Author:
Rajalakshmi G.,Dhanapal C.K.,Sundhararajan R.
Abstract
In pharmaceutical field, many drugs are being invented to combat the existing new diseases. The winds of change in the drug scenario are blowing forcefully worldwide. The emergence of new technologies provides an unique opportunities to exploit novel approaches in drug delivery. A shift from conventional drug delivery to novel drug delivery is noticed as shift from conventional drug delivery suffers from various drawbacks, But these new mighty compounds in drug therapy solely are not sufficient to meet the today’s need. There is an urgent need for the smart technology, as the drugs available suffer from serious problems like poor solubility and poor bioavailability. Most of the drugs that are available therapeutically comes under BCS class II ie, poorly soluble and high lipophilc. To assure progress in drug therapy, the development of new drugs merely is not sufficient. Issues arising in delivery of new drugs should also be addressed. Thus there is an emergent need to improve the bioavailability of these drugs, the only remedy or boon for such drugs is the discovery of some smart technologies which can improve the bioavailability of these drugs. Nano drug delivery systems are the one such universal approach which fulfills the lacuna, which exists in conventional drug delivery systems. These Nano drug delivery systems, improves the pharmacokinetic profiles of many drugs. In 1980 K. Eric Drexler developed and popularized the concept of nanotechnology. In this review a deep insight on Nano structured lipid carriers is discussed elaborating its birth, significant qualities compared to other colloidal systems, its structure, characteristics, preparation and application are spotted.
Key words: BCS class, Lipophilic, Nano technology, Nano structured lipid carrier.
Publisher
Society of Pharmaceutical Tecnocrats
Reference72 articles.
1. 1. Uner M, "Preparation, characterization and physico-chemical properties of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Their benefits as colloidal drug carrier systems" Pharmazie, 2006; 61: 375-386.
2. 2. Scheffel U, Rhodes BA, Natajaran TK, Wagner HN "Albumin microspheres for study of the reticuloendothelial system"J Nucl Med. 1970; 13:498-503.
3. 3. Jumaa M, Muller BW "Lipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: Mechanism of protective effect" Eur J Pharm Sci. 2000; 9: 285-90.
4. 4. Parashar AK, D. Chadhar KV, Devaliya R, Shrivastav V, Jain UK, "A review on Solid Lipid Nanoparticles (SLN) for controlled and targeted delivery of medicinal agents Current Research in Pharmaceutical Sciences" 2011; 02: 37-47.
5. 5. Manjunath K, Venkateswarlu V. "Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release" 2005, 107:215-28.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献